Why the study?
The underlying mechanisms of augmented cross-network functional communication between sensorimotor, default mode, and attentional networks in fibromyalgia are unknown.
How do momentary large-scale brain co-activation patterns and focal neurochemistry relate to hyperalgesia and cross-network functional connectivity in fibromyalgia?
How do momentary large-scale brain co-activation patterns and focal neurochemistry relate to hyperalgesia and cross-network functional connectivity in fibromyalgia?
Momentary large-scale topographic brain patterns shape noxious information in fibromyalgia patients, mediated by focal neurochemistry.
Hypothesis-generating for insula mechanisms in fibromyalgia hyperalgesia; leaves open causal targets for network connectivity.
Fibromyalgia has been characterized by augmented cross-network functional communication between the brain's sensorimotor, default mode, and attentional (salience/ventral and dorsal) networks. However, the underlying mechanisms of these aberrant communication patterns are unknown. In this study, we sought to understand large-scale topographic patterns at instantaneous timepoints, known as co-activation patterns (CAPs). We found that a sustained pressure pain challenge temporally modulated the occurrence of CAPs. Using proton magnetic resonance spectroscopy, we found that greater basal excitatory over inhibitory neurotransmitter levels within the anterior insula orchestrated higher cross-network connectivity between the anterior insula and the default mode network through lower occurrence of a CAP encompassing the attentional networks during sustained pain. Moreover, we found that hyperalgesia in fibromyalgia was mediated through increased occurrence of a CAP encompassing the sensorimotor network during sustained pain. In conclusion, this study elucidates the role of momentary large-scale topographic brain patterns in shaping noxious information in patients with fibromyalgia, while laying the groundwork for using precise spatiotemporal dynamics of the brain for the potential development of therapeutics.
No takes yet. Share an insight, caveat, or question.
Mawla et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: